Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
estimates increased at UBS through 2012, UBS said. Company boosted its guidance, aided by currency. Neutral rating and $29 price target.
estimates, target upped at Citigroup. AZO estimates were boosted through 2012, Citigroup said. Higher sales are driving wider margins. Hold rating and new $270 price target.
estimates, target raised at Goldman. Shares of AZO now seen reaching $262, according to Goldman Sachs. Estimates also increased, as higher sales are driving margin expansion. Sell rating.
target lowered at Citigroup to $15, Citigroup said. SEC inquiry could hang over the stock. Hold rating.
numbers upped at Goldman. FRX estimates were boosted through 2014, Goldman Sachs said. New COPD drug could reach peak annual sales of $250 million. Neutral rating and $35 price target.
estimates boosted at Goldman. MYGN estimates were upped through 2013, Goldman Sachs said. Company has pledged to buy back $100 million worth of stock. Sell rating and $17 price target.
numbers raised at Goldman. Shares of PAY now seen reaching $45, according to Goldman Sachs. Estimates also increased, to match the company's new guidance. Neutral rating.
numbers boosted at Citigroup. Shares of TECD now seen reaching $63, according to Citigroup. Estimates also upped, to match the company's new guidance. Buy rating.
numbers increased at Goldman. UHS estimates were raised through 2012, Goldman Sachs said. Business trends are stabilizing. Neutral rating and new $50 price target.
estimates increased at Goldman. WXS estimates were raised through 2012, Goldman Sachs said. Company has a strong competitive position and no exposure to lending or regulatory risk. Neutral rating.
This article was written by a staff member of TheStreet.